Pre-clinical data for Lovaxin C demonstrates an extremely robust immune response to tumors upon administration of the drug and eradication of tumors in more than half of the animals tested.
Unlike other products in late clinical trials, which are preventative vaccines against the HPV virus (the virus which causes cervical cancer), but cannot benefit woman already infected with the virus. The Advaxis vaccine, Lovaxin C is a therapeutic designed to treat women who have developed cervical cancer as a result of an HPV infection. Advaxis says that it is targeting this significant unmet medical need with the Lovaxin C vaccine.
“This Phase I/II trial is the first step in a comprehensive plan that will build on the strong pre-clinical results we have seen in more than a decade of development work,” said Roni Appel, president and CEO of Advaxis.